Macarena Roa

Hematologa.

[Macarena Roa @hemato_maca]

Fecha: [26 y 27 de Julio]
Horario: [8:30 am ]
Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura]

¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL #Linfoma #Networking #Hem… https://t.co/unHn9lLqeQ

[Macarena Roa @hemato_maca]

@castro_mollo @CaroPavlovsky @analymorac See you there. !!!!!😘

[Melanie Castro-Mollo @castro_mollo]

Add this session to your ASH schedule 📅 on Monday 8th December at 12:30pm at #ASH2025 Very excited to chair this session with amazing colleagues from across Latin America to discuss advances and challenges in leukemia. Looking forward to an inspiring conversation!
🇲🇽🇧🇷🇦🇷🇨🇱🇨🇴🇵🇪

[Macarena Roa @hemato_maca]

Honrada de ser reconocida por @ash_hematology con un Abstract Achievement Award.
Cada logro en investigación es fruto del trabajo colaborativo y de la inspiración de pacientes, mentores y colegas.
¡Nos vemos en #ASH25!
#Hematología #Investigación #Gratitud

[Lymphoma Hub @lymphomahub]

CONGRESS | #18ICML | PRESENTATION
Kate Cwynarski @CwynKate @uclh presents 7-year follow-up results from the phase II MARIETTA trial of multi-agent chemotherapy with MATRix and R-ICE followed by TT-ASCT in patients with SCNSL (N = 75).
Long-term follow-up results demonstrate durable remissions (7-year PFS, 64%) in patients who proceeded to TT-ASCT. The 7-year PFS rates were 52%, 33%, and 11% for patients with de novo SCNSL, isolated CNS relapse, and synchronous CNS relapse, respectively.
Follow our live feed for more updates: https://t.co/OURRpCKwai
#lymphoma #lymsm #MedicalCongress

[ASH @ASH_hematology]

A bright spot 🎇in a meeting full of light was seeing all the connections made at #ASH24.

Who did you meet at the meeting? Tag them below!

[Macarena Roa @hemato_maca]

@GabrielBoric @ximenaguilera Estimado Presidente. Soy Médico y trabajo en el sistema publico . Creo humildememte que la salud publica mejoraria drasticamente con 1 sola medida: que todas las autoridades : ministros ,parliamentarios, jueces, e incluso ud, al asumir deban atenderse en el Sistema publico.

[Macarena Roa @hemato_maca]

@TheIndexKiller Hola. En qué plataforma compras las acciones del índice.?

[Ahmed Kotb @AhmedKo45911157]

👌ECHELON-3 🆕️ is the first randomized, placebo-controlled, phase 3 study to demonstrate overall survival benefit in a
contemporary population of patients with R/R DLBCL who have received 2or more prior lines of systemic therapy
💊BV+Len+R met its primary objective
#SOHO2024

[Lymphoma Hub @lymphomahub]

A new study published in @TheLancetHaem found that epcoritamab was associated with an ORR of 82% in patients with R/R follicular #lymphoma📝 
More news: https://t.co/xVXjzsqQhA
#lymsm #MedNews #MedEd

[Macarena Roa @hemato_maca]

Para @iHematologo Podría convertirse en tu tema favorito

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

👏👏 Super kudos to @pmcancercentre @rkridel for this outstanding translational work in follicular #lymphoma.

From 713 tumor tissue samples (eg, E4402, E2408 & GALLIUM), 5 genetic subtypes discovered and a/w clinicopath findings & pt outcomes.

👉👉 SEE: https://t.co/xJ1BrUCSSB

[Toby Eyre @tobyeyre82]

Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma: Expert Review of Hematology: Vol 0, No 0 - Get Access https://t.co/OUTPIxccsP

[Graham Collins @graham74GC]

Front line treatment of Hodgkin Lymphoma with PET-adapted BrECADD vs escBEACOPP.

BrECADD wins the day. Can it be beaten…? #lymsm

https://t.co/bAA5PKDVSo

[GELTAMO @geltamo]

Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma https://t.co/130U48qpMl

[Kate Cwynarski @CwynKate]

SPOTLIGHT REVIEW
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma
Megan Melody
Leo I. Gordon

@Haematologica
https://t.co/OZy8YHaXpl

[Targeted Oncology @TargetedOnc]

Zanubrutinib, obinutuzumab, and venetoclax (the BOVen regimen) was safe and produced responses in older patients with #MCL, according to data from the phase 2 trial. #EHA24 #EHA2024 | @MSK_DeptOfMed

https://t.co/KsdK84UEMK

[Macarena Roa @hemato_maca]

Prepárate para una experiencia de aprendizaje, networking y buena onda en la 2da jornada del GCEL!
26 y 27 de Julio 2024
Double tree by Hilton , av. Kennedy 4422, Vitacura
Únete a nosotros y forma parte del cambio en el tratamiento de los linfomas. ¡No faltes!

[Ana Lisa Basquiera @basquiera]

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma https://t.co/CDvMofb1EZ

[Macarena Roa @hemato_maca]

Fecha: [26 y 27 de Julio]
Horario: [8:30 am ]
Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura]

¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL #Linfoma #Networking #Hematología

[Grupo Chileno de Estudio de Linfoma @GLinfoma]

¡No te pierdas la segunda jornada del Grupo Chileno de Estudio del Linfoma (GCEL)!

Te invitamos a participar de esta imperdible cita que reunirá a algunos de los profesionales más destacados en el estudio y tratamiento del linfoma en Chile y en Latinoamérica.